Teva Wins FDA Nod for At-Home Use of Igalmi in Schizophrenia Agitation
TEVA sits 82% above its 52-week low of $24.01.
Summary
Teva secured an at-home indication for Igalmi in agitation associated with schizophrenia, expanding the drug beyond its prior supervised-use setting. The label broadening matters because at-home dosing opens a much larger addressable population than clinic- or ER-administered treatment, and it builds on the October FDA approval of Teva's monthly olanzapine injection for schizophrenia. This is a modest but real pipeline win for a company whose growth story leans on innovative medicines, following the Q3 beat and raised guidance on November 3 and the R&D Day targets of $6-7B in innovative revenue by 2030. Shares are trading near a 52-week high, so the news lands into an already-strong tape. BTAIQ, the other tagged ticker, is not a party to this approval.
At the time of this announcement, TEVA was trading at $43.62 on NYSE in the Life Sciences sector, with a market capitalization of approximately $50.9B. The 52-week trading range was $24.01 to $44.57. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.